Sign In
Buy KYKOF
$14.20
+0 (+0%)
At Close: Jul 31, 2026
Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation at American Academy of Dermatology 2024 Meeting
07:00am, Wednesday, 14'th Feb 2024
PRINCETON, N.J. and TOKYO , Feb. 14, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
TOKYO , Feb. 6, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, parall
LONDON--(BUSINESS WIRE)--Adults living with the rare disease X-linked hypophosphataemia (XLH) in England and Wales risk missing out on an innovative treatment following an initial decision by NICE not
Claims database analyses show increasing prevalence and impact of XLH-related morbidities with age, underscoring life-long burden of disease PRINCETON, N.J. , Oct. 16, 2023 /PRNewswire/ -- Kyowa Kirin
Kyowa Kirin to Present New Research on X-linked Hypophosphatemia (XLH) at ASBMR Annual Meeting
09:00am, Thursday, 12'th Oct 2023
Five poster presentations provide greater understanding of patient profiles and real-world experiences of people living with XLH PRINCETON, N.J. , Oct. 12, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an a
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
07:00am, Wednesday, 11'th Oct 2023
TOKYO , Oct. 11, 2023 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational produ
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
04:36am, Thursday, 05'th Oct 2023
Japanese pharmaceutical firm Kyowa Kirin said on Thursday it would acquire Britain-based biopharmaceutical company Orchard Therapeutics for $477.6 million, aiming to promote the development of new dru
Kyowa Kirin Announces Acceptance for Presentations at the European Academy of Dermatology and Venereology Congress 2023
02:22pm, Wednesday, 04'th Oct 2023
TOKYO , Oct. 4, 2023 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product being
Kyowa Kirin: High-Risk High-Return Call Reiterating Our Buy Rating
11:33pm, Sunday, 24'th Sep 2023
Kyowa Kirin shares are viewed as a cheap option on the positive outcome for the atopic dermatitis drug being developed with Amgen. The company's recent track record for new drug trial success has been
Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.
02:10am, Thursday, 21'st Sep 2023
TOKYO--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the acceptance of an extensive programme of data to the annual meeting of the
Titian Software Supporting Kyowa Kirin's Central Sample Bank
09:11am, Tuesday, 29'th Aug 2023
LONDON--(BUSINESS WIRE)--Titian Software and ITOCHU Techno-Solutions announce the deployment of Titian's Mosaic Sample Management Software to support Kyowa Kirin's Central Sample Bank at their R&D sit
Kyowa Kirin Designs New North American Headquarters to Accelerate Innovation, Collaboration, Culture
08:30am, Tuesday, 11'th Jul 2023
Japan-Based Specialty Pharmaceutical Company Moves Into Princeton, NJ, Offices PRINCETON, N.J. , July 11, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd.
Kyowa Kirin To Cut Royalty Payment Rate To Ardelyx For Tenapanor In Cardiorenal Disorders
01:30pm, Monday, 11'th Apr 2022
Ardelyx Inc (NASDAQ: ARDX) has amended its license agreement, initially executed in 2017, granting Kyowa Kirin exclusive rights to develop and commercialize Ardelyx's tenapanor for cardiorenal dis
MEI Pharma, Kyowa Kirin Reveal Data From Zandelisib Trial In Follicular Lymphoma
10:09am, Tuesday, 30'th Nov 2021
MEI Pharma Inc (NASDAQ: MEIP) and Kyowa Kirin Co Ltd have announced data from the pivotal Phase 2 TIDAL study of zandelisib as a single agent for follicular lymphoma (FL) patients who received at
